Skip to main navigation

Investor Relations

Overview
News & Events
- Press Releases
- Events & Presentations
Stock Information
Financials
- SEC Filings
- Quarterly Results
Governance
IR Resources

Press Releases

Year

Oct 27, 2022

Kiromic BioPharma Arranges Up to $10 Million Financing

Oct 06, 2022

Kiromic BioPharma Announces FDA Feedback from Type B Pre-IND Meeting Confirms Deltacel Development Strategy

Jul 12, 2022

Kiromic BioPharma Appoints Leonardo Mirandola, Ph.D. as Chief Scientific Officer

Jul 07, 2022

Kiromic BioPharma Achieves Milestone with Timely Completion of Expanded cGMP Manufacturing Facility to Support Cell Therapy Oncology Pipeline

Jun 21, 2022

Kiromic BioPharma Pipeline to Prioritize a New Gamma Delta T-cell Product Candidate

Jun 07, 2022

Kiromic BioPharma Significantly Expands Gamma Delta T cell Product Pipeline with New Sponsored Research Agreement

May 13, 2022

Kiromic BioPharma Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

May 11, 2022

Kiromic BioPharma Announces Company Will Directly Submit Amended IND for Procel™ to the FDA in Second Half of 2022

Apr 11, 2022

Kiromic BioPharma Announces Availability of Company’s Current Corporate Presentation

Apr 08, 2022

Kiromic BioPharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Highlights

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 14

Investor Tools

Print

RSS Feeds

Email Alerts

Investor Contact

Copyright © 2022 Kiromic BioPharma, Inc. All rights reserved.